Last reviewed · How we verify
NCT06229353
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
trial testing Gardasil 9 in Human Papilloma Virus in 34 participants. Terminated before completion.
30 July 2025
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 34 |
| Start date | 8 August 2024 |
| Primary completion | 30 July 2025 |
| Estimated completion | 30 July 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Gardasil 9
Conditions studied
- Human Papilloma Virus — all drugs for Human Papilloma Virus →
Sponsor
University of Alabama at Birmingham
Who can join
Adults 18 to 45, any sex, with Human Papilloma Virus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine if the emergency department (ED) setting offers a viable space for improving HPV vaccination coverage among 18 to 45-year-old adults who have not yet received human papilloma virus (HPV) vaccination or who did not complete the vaccine series. This study will develop, pilot and evaluate an ED-based HPV vaccination protocol and program for ED patients aged 18-26 (for whom catch-up HPV vaccination is routinely recommended by the CDC) and separately for patients aged 27-45 (for whom it may be recommended under shared decision making, SDM).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06229353
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Gardasil 9
Trials testing the same drug.
- NCT06536855 — Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstra · Phase 4 · not yet recruiting
- NCT05496231 — A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 t · Phase 1, PHASE2 · completed
- NCT03519464 — Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytop · Phase 2 · active not recruiting
Other recruiting trials for Human Papilloma Virus
Currently open trials in the same condition.
- NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
- NCT06414057 — HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks · recruiting
- NCT06747390 — Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery · Phase 1 · recruiting
- NCT06598176 — Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples · NA · recruiting
- NCT05996783 — Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial · NA · active not recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06229353 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06229353.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing